The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Electronic provider notification led to more aortic valve replacement procedures after a diagnosis of severe aortic stenosis vs. usual care. There was a trend toward the intervention reducing ...

Adhering to the principles of evidence-based medicine, Venus Medtech has consistently conducted long-term follow-up studies ...

A warning to stop using certain Novasight Hybrid diagnostic intravascular catheters was distributed by the FDA. Moderate- and ...

This study aimed to assess impact of atrioventricular valve (AVV) regurgitation onset, timing of AVV repair (AVVr), ventricular morphology, and era effect on AVVr outcomes in a single ventricle ...

Edwards Lifesciences Corporation ( NYSE: EW) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - ...

View all available purchase options and get full access to this article.

Inc. (Stock Code: 2500.HK, hereinafter referred to as 'Venus Medtech' or the 'Company'), a global leader in structural heart therapies, has announced financial results for the year ended December 31, ...